Myeloma Minute: Darzalex, Value, Costs: What’s Ahead @ ASCO 2016?


ASCO 2016: More Excitement About Daratumumab (Darzalex®) and Tremendous Interest in Value and Costs

As usual, far fewer myeloma-related abstracts will be presented at next month’s annual meeting of the American Society of Clinical Oncology (ASCO) than are presented at the annual meeting of the American Society of Hematology (ASH) each December. But, writes IMF Chairman Dr. Brian Durie in his blog this week, the results of the Phase III CASTOR study have created some excitement, and the subjects of “cost” and “value” in cancer treatment are definitely in the air! To read Dr. Durie’s blog, click HERE.


Don't Miss the "Living Well with Myeloma" Teleconference on Overcoming Side Effects

The IMF’s "Living Well with Myeloma” quarterly teleconference series is designed to cover all the important and most up-to-date information regarding multiple myeloma. The next teleconference will be broadcast on June 7, 2016 at 7 PM ET / 4 PM PT. This sixty-minute question-and-answer session will discuss what patients need to know to overcome side effects from novel therapies. Speakers will be Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN®, of the Cleveland Clinic Taussig Cancer Institute and Kevin Brigle, PhD, NP of the VCUHS Massey Cancer Center. To register, click HERE.


Calling All Researchers: Submit Your Grant Applications for the 2016 Brian D. Novis Research Awards

The Brian D. Novis Research Awards honor the IMF’s founder Brian Novis, who died of multiple myeloma in July of 1992. The awards go to researchers doing work in the field of multiple myeloma and related disorders including smoldering myeloma, MGUS (monoclonal gammopathy of undetermined significance), as well as immunoglobulin-derived amyloidosis. The 2016 awards are $50,000 each for junior grants and $80,000 for senior grants. August 1, 2016 is the deadline for applications. For more information and grant applications, click HERE.

New IMF Video Focuses on Myeloma Patients Who Are Taking Ninlaro

In November 2015, the FDA approved Ninlaro for the treatment of multiple myeloma in combination with Revlimid and dexamethasone for patients who have had one prior therapy. In a new video, patients who have been on this drug regimen for the past few years as part of clinical trials describe their experiences. One patient comments that Ninlaro has allowed him to lead “as close to a normal life as possible while having cancer.” Because it is the first-approved oral proteasome inhibitor, Ninlaro can be taken at home, by mouth. Also discussed in this video are the dosing regimens for Ninlaro, its possible side effects, and how doctors can begin to determine if the drug is a good choice for certain patients. To view this video, click HERE.


Outstanding Family Hosts Their 9th Annual Golf Tournament to Benefit the IMF's Research Program

In 2000, the Czerkies’ mother Carolyn passed from complications of multiple myeloma. In 2008, brothers Craig, David, and Scott came together to organize their first IMF fundraiser as a tribute to their mother’s battle with myeloma. Since that time, their yearly golf outings have raised more than $225,000. Of note, the golf outing they held last year was one of the IMF’s largest charity events. This year’s 9th Annual Carolyn Czerkies Memorial Golf Outing takes place at 1 pm CT on Saturday, June 4th at Joliet Country Club in Joliet, Illinois. To attend or to donate, click HERE.

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.